by Osteogenesis imperfecta, commonly known as brittle bone disease, is a rare genetic disorder characterized by bones that break easily, often from little or no apparent cause. The current treatment options for osteogenesis imperfecta include bisphosphonates, such as pamidronate (Aredia) and zoledronic acid (Reclast), which help build stronger bones and prevent fractures. Other treatment options include physical therapy and occupational therapy to improve mobility and daily living skills.
The global osteogenesis imperfecta treatment market is estimated to be valued at US$ 832.67 Mn in 2024 and is expected to exhibit a CAGR of 4.2% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the osteogenesis imperfecta treatment market are AmSurg Corp., HCA Holdings, Inc., Tenet Healthcare, Surgical Care Affiliates, Inc., Surgery Partners, Ambulatory Surgical Centers of America, Heathway Medical Group, Community Health Systems, Inc., and Vision Group Holdings. The key players are focusing on new product launches and approvals to expand their market share. For instance, in 2021, Chugai Pharmaceutical received FDA approval for Evamisit for treatment of osteogenesis imperfecta in children and adolescents.
The key opportunities in the osteogenesis imperfecta treatment market include rising awareness about the disease and its treatment options. Moreover, growing research activities for development of novel and more effective drugs are also likely to present growth opportunities for players in the market.
Globally, North America dominates the Osteogenesis Imperfecta Treatment Market Growth due to high awareness levels about the disease and availability of advanced treatment options. Moreover, growing research activities for development of new drugs in the US and Canada are boosting the regional market growth. However, Asia Pacific is expected to exhibit lucrative growth during the forecast period owing to rising diagnosis rate and improving healthcare infrastructure in major countries.
Market Drivers
Rising incidence of osteogenesis imperfecta coupled with growing disease awareness is a major factor contributing to the growth of global osteogenesis imperfecta treatment market. According to studies, the incidence of osteogenesis imperfecta is estimated to be 1 in 15,000 to 20,000 live births globally. Moreover, increasing research funding by public and private organizations for development of improved treatment is also boosting the market growth. For instance, the National Institutes of Health provides funding support for research studies focused on better understanding the pathogenesis of osteogenesis imperfecta and development of novel therapies.
PEST Analysis
Political: Government regulations on product approval and quality standards affect the treatment development process. Favourable regulations can boost the market growth.
Economic: Rising healthcare spending coupled with growing per capita income is positively impacting the market. However, high treatment costs can hamper the market growth.
Social:Growing public awareness about managing rare disorders and available treatment options is driving the demand for osteogenesis imperfecta treatment.
Technological: Advancements in treatment technologies like gene therapy and 3D bioprinting are creating new opportunities. Development of advanced therapeutics can improve treatment outcomes.
Geographical concentration of market in terms of value
North America dominates the market and accounted for majority share in 2024 due to growing patient pool, presence of key players, and availability of advanced treatment options in the region.
Fastest growing region
Asia Pacific region is expected to grow at fastest pace during the forecast period due to rising healthcare expenditures, increasing diagnosis rates, and growing medical tourism industry in emerging countries like China and India.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
